Picture Berlin Partner Bionnale 2021 Digital Event 650x80px
Document › Details

ProteoNic B.V.. (10/20/20). "Press Release: ProteoNic Announces Licensing of Technology for Production of Biologics to Immunomedics". Leiden.

Organisations Organisation ProteoNic Biotechnology B.V.
  Organisation 2 Immunomedics Inc. (Nasdaq: IMMU)
  Group Gilead Sciences (Group)
Products Product 2G UNic™ expression technology
  Product 2 therapeutic protein
Index term Index term Gilead–ProteoNic: rec protein production technology, 202010– licensel €na to use 2G UNic technology to Immunomedics
Persons Person Posno, Mark (ProteoNic 201902 VP Business Development)
  Person 2 Melens, Léon (LifeSpring Life Sciences Communication 2016– Founder before SPJ since 1998)

ProteoNic BV, a leading provider of technology and services in the field of production of biologics, today announced it has licensed its premium 2G UNic™ technology for boosting therapeutic protein production to Immunomedics, Inc. (NASDAQ: IMMU), a biopharmaceutical company developing immuno-therapeutics for the treatment of cancer and other diseases.

Under the agreement, Immunomedics gains commercial rights for application of ProteoNic’s technology platform to the development of specified proprietary products from mammalian cells. Financial details of the agreement were not disclosed.

ProteoNic’s protein expression technology improves production levels across a range of host cells, selection systems and protein targets. It increases transcription and translation rates via a combination of novel genetic elements, which together exert a powerful positive effect on recombinant protein production levels without impacting product quality or cell line stability attributes. 2G UNic™ can be readily combined with other protein expression-enhancing technologies to improve their performance.

Mark Posno, Vice President of Business Development of ProteoNic commented: “We are pleased that we can contribute to improving the efficiency of production of Immunomedics’ antibody-based products. ProteoNic’s clients consistently achieve strongly increased cell line productivity and reduced manufacturing cost. We will continue our work towards reaching the maximum potential of the production of biologicals for current and future clients”.

About ProteoNic

ProteoNic is a privately held company with offices in Leiden, the Netherlands and in the Boston area, USA. The company offers technology and services for the generation of cell lines with greatly improved biologics production characteristics, including production levels and stability. The company commercializes its proprietary 2G UNic™ technology through licensing and partnership arrangements.


ProteoNic BV
Mark Posno, PhD
Vice President Business Development
+1 617 480 8016

LifeSpring LifeSciences Communication, Amsterdam, the Netherlands
Leon Melens
+31 6 538 16427

Record changed: 2021-01-05


Picture EBD Group Global Partnering Four Events One Price 650x80

More documents for ProteoNic Biotechnology B.V.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group ChinaBio Partnerting Forum 2021 651x80

» top